Skip to main content

Table 1 Comparison of clinicopathological features between epidermal growth factor receptor mutant and mutation-wild patients with pathological stage IB-IIIA lung cancer

From: Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status

Total n = 535 Mt (n = 208) Wt (n = 358) p valuesa)
Age 70 (35–90) 70 (36–90) 0.789b)
Male, (%) 86 (41.3) 260 (72.6) < 0.001
Smoking history +, (%) 93 (44.7) 287 (80.2) < 0.001
Left side, (%) 74 (35.6) 142 (39.7) 0.370
CEA (> 10 ng/ml) 34 (16.3) 61 (17.0) 0.907
CT tumor size, (cm) 3.1 (1.5–9.2) 3.4 (0.8–11.6) 0.033b)
Consolidation size, (cm) 2.7 (1.1–9.2) 3.2 (0.6–11.0) 0.001b)
GGO absent, (%) 128 (61.5) 306 (85.5) < 0.001
PET maxSUV 4.9 (0.89–21.2) 7.4 (0–33.7) < 0.001b)
Lobectomy 199 (95.7) 334 (93.3) 0.270
Invasive lepidic adenocarcinoma, (%) 24 (11.5) 24 (6.7) 0.060
Invasive acinar adenocarcinoma, (%) 78 (37.5) 76 (21.2) < 0.001
Invasive papillary adenocarcinoma, (%) 77 (37.0) 85 (23.7) 0.001
Invasive mucinous adenocarcinoma, (%) 1 (0.5) 44 (12.3) < 0.001
Invasive solid adenocarcinoma, (%) 14 (6.7) 104 (29.1) < 0.001
Invasive micropapillary adenocarcinoma, (%) 11 (5.3) 4 (1.1) 0.004
High-grade adenocarcinoma 28 (13.5) 126 (45.2) < 0.001
Lymphatic vessel invasion +, (%) 78 (37.5) 86 (24.0) 0.002
Blood vessel invasion +, (%) 122 (58.7) 198 (56.3) 0.482
Pleural invasion +, (%) 125 (60.1) 197 (55.3) 0.253
Nodal metastasis +, (%) 107 (51.4) 125 (34.9) < 0.001
 pN1 47 (22.6) 66 (18.4) 0.233
 pN2 60 (28.8) 59 (16.5) < 0.001
Lepidic component +, (%) 185 (88.9) 195 (54.5) < 0.001
Solid component +, (%) 109 (52.4) 240 (67.0) < 0.001
Micropapillary component +, (%) 121 (58.2) 128 (35.8) < 0.001
Adjuvant chemotherapy, (%) 84 (40.4) 124 (34.6) 0.176
Pathological stage
 Stage IB 82 (39.4) 142 (39.7)  
 Stage II 54 (26.0) 128 (35.8)  
 Stage IIIA 72 (34.6) 88 (24.6) 0.014
Recurrence +, (%) 92 (44.2) 121 (33.8) 0.015
Initial site of recurrence, (%)
 Central nerve system 17 (8.2) 16 (4.5) 0.192
 Bone 21 (10.1) 23 (6.4) 0.143
 Abdominal organ 10 (4.8) 24 (6.7) 0.463
 Lung 29 (13.9) 41 (11.5) 0.428
 Cervico-thoracic lymph-node 38 (18.3) 43 (12.0) 0.047
 Pleural dissemination 23 (11.1) 15 (4.2) 0.003
Distant or intrathoracic, (%)
 Distant 37 (17.8) 57 (15.9) 0.639
 Intrathoracic 76 (36.5) 84 (23.5) 0.001
EGFR mutation, (%)
 Exon 21 L858R 96 (46.2)   
 Exon 19 deletion 112 (53.8)   
  1. CT Computed tomography, GGO Ground glass opacity, PET Positron emission tomography, SUV Standardized uptake value, EGFR Epidermal growth factor receptor, Mt EGFR mutant lung cancer, Wt EGFR mutation-wild lung cancer
  2. a Fisher’s exact test
  3. b Mann-Whitney U test